RHYTHM PHARMACEUTICALS INC

NASDAQ: RYTM (Rhythm Pharmaceuticals, Inc.)

Kemas kini terakhir: 6 minit lalu

98.31

0.07 (0.07%)

Penutupan Terdahulu 98.24
Jumlah Dagangan 691,882
Harga / Pendapatan (P/E Ke hadapan) 526.32
Harga / Jualan (P/S) 27.61
Harga / Buku (P/B) 65.68
Julat 52 Minggu
74.50 (-24%) — 122.20 (24%)
Margin Keuntungan -123.28%
Margin Operasi (TTM) -143.73%
EPS Cair (TTM) -2.80
Pertumbuhan Hasil Suku Tahunan (YOY) 25.90%
Jumlah Hutang/Ekuiti (D/E MRQ) 69.65%
Nisbah Semasa (MRQ) 3.30
Aliran Tunai Operasi (OCF TTM) -113.49 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -96.71 M
Pulangan Atas Aset (ROA TTM) -51.33%
Pulangan Atas Ekuiti (ROE TTM) -150.20%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok Rhythm Pharmaceuticals, Inc. Bercampur Menaik

AISkor Stockmoo

-0.6
Konsensus Penganalisis NA
Aktiviti Orang Dalam -1.5
Volatiliti Harga 2.0
Purata Bergerak Teknikal -2.5
Osilator Teknikal -0.5
Purata -0.63

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
RYTM - - - 65.68
ARWR - - - 20.55
ENTX - - - 71.13
LPCN - - - 0.810
ARDX - - - 6.29
CYTK - - - 60.31

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 0.65%
% Dimiliki oleh Institusi 103.78%

Pemilikan

Nama Tarikh Syer Dipegang
Ra Capital Management, L.P. 30 Jun 2026 6,666,837
Vanguard Group Inc 31 Dec 2025 6,210,916
Blackrock, Inc. 30 Jun 2026 6,156,902
Baker Bros. Advisors Lp 30 Jun 2026 5,604,483
Primecap Management Co/Ca/ 30 Jun 2026 3,168,853
Vanguard Portfolio Management Llc 30 Jun 2026 3,136,895
Vanguard Capital Management Llc 30 Jun 2026 3,005,977
Jpmorgan Chase & Co 30 Jun 2026 2,652,746
Perceptive Advisors Llc 30 Jun 2026 2,586,295
State Street Corp 30 Jun 2026 2,573,529
Price T Rowe Associates Inc /Md/ 30 Jun 2026 2,566,171
Westfield Capital Management Co Lp 30 Jun 2026 2,208,595
Federated Hermes, Inc. 30 Jun 2026 1,785,716
Polar Capital Holdings Plc 30 Jun 2026 1,663,632
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
MEEKER DAVID P - 102.44 -50,000 -5,122,000
Jumlah Keseluruhan Kuantiti Bersih -50,000
Jumlah Keseluruhan Nilai Bersih ($) -5,122,000
Purata Pembelian Keseluruhan ($) -
Purata Jualan Keseluruhan ($) 102.44
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
MEEKER DAVID P Pegawai 14 Sep 2026 Jual automatik (-) 50,000 102.44 5,122,000
MEEKER DAVID P Pegawai 14 Sep 2026 Pelaksanaan pilihan 50,000 - -

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda